Trident Lifeline Share News - Latest Updates, Live News & More

Latest news about Trident Lifeline

Trident Lifeline Promoter Group Member Reduces Shareholding Through Open Market Transactions 1 day ago Yesterday

Promoter group member Amit Bhupendrabhai Halvawala of Trident Lifeline Limited disclosed the sale of 34,800 equity shares through open market transactions on 27.03.2026 and 30.03.2026. His shareholding decreased from 1,36,300 shares (1.14%) to 1,01,500 shares (0.85%) of the company's total share capital. The transactions were conducted in compliance with SEBI regulations, with the company's equity share capital remaining unchanged at Rs. 11,93,30,000.

Trident Lifeline Promoter Rinkal Gajera Reduces Shareholding Through Open Market Sales 1 day ago Yesterday

Hardik Desai Family Trust Increases Stake in Trident Lifeline Limited Through Open Market Purchase 1 day ago Yesterday

Trident Lifeline Promoter Rupaben Jariwala Reduces Stake Through Open Market Sales 2 days ago

Trident Lifeline Limited Conducts Independent Directors Meeting on March 28, 2026 5 days ago

More news about Trident Lifeline

27Mar 26

Trident Lifeline: Promoter Group Member Niyati Roshan Thakkar Reduces Stake to 0.54%

Niyati Roshan Thakkar, promoter group member of Trident Lifeline Limited, has reduced her shareholding from 1.01% to 0.54% through an off-market sale of 55,800 shares on March 24, 2026. The transaction was disclosed under SEBI regulations, with the company's equity capital structure remaining unchanged at Rs. 11,93,30,000 comprising 1,19,33,000 shares of Rs. 10 each.

27Mar 26

Trident Lifeline Promoter Hardik Desai Increases Stake to 23.11% Through Off-Market Acquisition

Hardik Jigishkumar Desai, promoter and director of Trident Lifeline Limited, acquired 55,800 additional equity shares through an off-market transaction on March 24, 2026. This acquisition increased his total shareholding from 27,02,150 shares (22.64%) to 27,57,950 shares (23.11%) of the company's share capital. The transaction was disclosed in compliance with SEBI regulations, with the company's equity share capital remaining unchanged at ₹11,93,30,000 comprising 1,19,33,000 equity shares of ₹10 each.

18Mar 26

Trident Lifeline Limited Increases Shareholding in Subsidiary Trident Mediquip Limited to 59.77%

Trident Lifeline Limited has acquired an additional 2.67% equity stake in subsidiary Trident Mediquip Limited, increasing shareholding from 57.10% to 59.77%. The subsidiary operates in pharmaceuticals with turnover of 21.29 Cr and paid-up capital of Rs. 9,81,58,000. The transaction is a related party deal conducted on arm's length basis, disclosed under SEBI regulations on March 18, 2026.

16Mar 26

Hardik Desai Family Trust Discloses Share Acquisition in Trident Lifeline Limited

Hardik Desai Family Trust acquired 4,200 shares of Trident Lifeline Limited through open market transactions on 12.03.2026, increasing its holding from 8,38,766 to 8,42,966 shares. This acquisition raised the trust's ownership stake from 7.03% to 7.06% of the total share capital. The disclosure was filed under SEBI regulations, with the trust maintaining its status as a promoter group entity in the company.

03Mar 26

Trident Lifeline's Shareholding in Subsidiary Trident Mediquip Reduces to 57.34% After Private Placement

Trident Lifeline Limited's shareholding in subsidiary Trident Mediquip Limited has decreased from 60.04% to 57.34% following a private placement of equity shares to other shareholders. Trident Mediquip, incorporated in 2019, operates in the pharmaceuticals and chemical industry with a current turnover of 21.29 crores and paid-up share capital of Rs. 9.78 crores. The transaction has been disclosed under SEBI regulations as a related party transaction conducted on an arm's length basis.

23Feb 26

Hardik Desai Family Trust Increases Stake in Trident Lifeline Limited to 6.99%

Hardik Desai Family Trust disclosed the acquisition of 1,200 additional shares in Trident Lifeline Limited through open market purchase on 20.02.2026. The acquisition increased the promoter group entity's holding from 8,32,766 shares (6.98%) to 8,33,966 shares (6.99%), representing a marginal 0.01% increase. The disclosure was made under SEBI regulations, with the company maintaining its equity share capital at Rs. 11,93,30,000 comprising 1,19,33,000 shares of Rs. 10 each.

23Feb 26

Trident Lifeline Promoter Rupaben Jariwala Reduces Stake Through Open Market Sale

Rupaben Chetanbhai Jariwala, promoter of Trident Lifeline Limited, sold 27,000 equity shares through open market transactions on February 20, 2026, reducing her shareholding from 6,89,500 shares (5.78%) to 6,62,500 shares (5.55%). The transaction represents 0.23% of the company's total share capital. The disclosure was made in compliance with SEBI regulations, with the company's equity share capital remaining unchanged at Rs. 11,93,30,000 comprising 1,19,33,000 shares of Rs. 10 each.

03Feb 26

Trident Lifeline Promoter Rupaben Jariwala Increases Stake Through Open Market Purchase

Rupaben Chetanbhai Jariwala, promoter of Trident Lifeline Limited, acquired 15,600 additional shares through open market purchase on 02.02.2026, representing 0.13% of total share capital. Her total shareholding adjusted to 7,02,700 shares or 5.89% of the company's voting capital. The disclosure was made in compliance with SEBI regulations for substantial share acquisitions.

02Feb 26

Trident Lifeline Limited Announces Bonus Share Allotment by Subsidiary Trident Mediquip Limited

Trident Lifeline Limited has announced that its subsidiary Trident Mediquip Limited completed a bonus share allotment, with Trident Lifeline receiving 9,34,160 new shares while maintaining its 60.04% shareholding percentage. The subsidiary operates in the pharmaceuticals industry with a turnover of 21.29 crore and paid-up share capital of Rs. 9,33,60,000. The transaction was disclosed under SEBI regulations as a related party transaction conducted on an arm's length basis.

20Jan 26

Trident Lifeline Reports Strong Q3FY26 Results with 44% Revenue Growth

Trident Lifeline Limited reported strong Q3FY26 results with 44% YoY revenue growth to ₹2,456.30 lakh and 53% EBITDA growth to ₹717.32 lakh, maintaining healthy margins at 29%. Nine-month performance showed 50% revenue growth and 40% EBITDA expansion. The export-focused pharmaceutical company operates across 44 countries with 1,070 registered products and 2,458 registrations in process, positioning for continued growth through its hybrid manufacturing model.

27Dec 25

Trident Lifeline Converts 135,000 Warrants Worth ₹2.69 Crores on December 27

Trident Lifeline Limited successfully converted 135,000 warrants into equity shares on December 27, 2025, raising ₹2.69 crores from two warrant holders at ₹266 per share. The conversion increased the company's paid-up capital to ₹11.93 crores with 11,933,000 total equity shares, following full regulatory compliance under SEBI guidelines.

16Dec 25

Trident Lifeline Converts 1,00,200 Warrants, Raises ₹1.99 Crores in Latest Board Action

Trident Lifeline Limited's board approved conversion of 1,00,200 warrants into equity shares on December 16, 2025, raising ₹1.99 crores at ₹266 per share. The conversion involved Hardik Desai Family Trust and Maniya H Desai, increasing the company's paid-up capital to ₹11.80 crores with total equity shares reaching 1,17,98,000. With 8,94,000 warrants still pending conversion, the company maintains significant potential for further capital expansion.

12Nov 25

Trident Lifeline Reports 52% Jump in Half-Year Revenue, Consolidated Profit Rises 49%

Trident Lifeline Limited (TLL) announced robust financial results for the half year ended September 30, 2025. The company's consolidated revenue surged 82% year-over-year to ₹5,335.68 crores. Net profit increased by 49% to ₹801.13 crores, while EPS improved by 47% to ₹6.91. TLL's standalone revenue rose 52% to ₹4,625.86 crores, with net profit up 31% to ₹841.71 crores. The company's strong performance is attributed to its diversified business model and strategic acquisitions across multiple subsidiaries in the pharmaceutical and healthcare sectors.

30Jul 25

Trident Lifeline Reports 27% Revenue Growth in Q1FY26

Trident Lifeline Limited reported robust Q1FY26 financial results. Revenue increased by 27% to ₹1,935.48 lakh, EBITDA grew 20% to ₹546.36 lakh, and profit after tax rose 15% to ₹347.59 lakh. The company operates in 43 countries with 1,035 registered export products and 2,329 in process. Trident maintains a diverse product portfolio of 3,364 items across various therapeutic categories. Management expressed satisfaction with the performance and anticipates continued growth driven by organic and inorganic expansion strategies.

28Jul 25

Trident Lifeline Reports Robust Q1 Results, Appoints New Secretarial Auditor

Trident Lifeline Limited announced its Q1 financial results, showing strong performance. Standalone net sales were Rs 2,084.65 lacs with a net profit of Rs 347.59 lacs. Consolidated net sales reached Rs 3,401.07 lacs with a net profit of Rs 306.28 lacs. The Board approved the appointment of M/s. Amareliya & Associates as Secretarial Auditor for five years, subject to shareholder approval. No investor complaints were pending during the quarter.

16Apr 25

Trident Lifeline Approves Issue of Convertible Warrants, Plans to Raise Up to ₹26.57 Crore

Trident Lifeline's Board of Directors has approved the issuance of 9,99,000 fully convertible warrants at ₹266 each, potentially raising ₹26.57 crore. The warrants are convertible into equity shares within 18 months of allotment. The company also plans to increase its Authorized Share Capital from ₹12 crore to ₹15 crore, subject to shareholder approval. An EGM is scheduled for May 9, 2025, to seek necessary approvals.

09Apr 25

Trident Lifeline to Consider Fund Raising and Share Capital Increase in Upcoming Board Meeting

Trident Lifeline Limited has scheduled a board meeting for April 16, 2025, to discuss and potentially approve significant financial initiatives. The agenda includes increasing authorized share capital, issuing equity shares or convertible warrants on a preferential basis, and setting up an Extra-Ordinary General Meeting (EGM) for shareholder approval. The company has closed the trading window for insiders from April 1, 2025, until 48 hours after the declaration of audited financial results for the quarter and year ended March 31, 2025.